Malaria vaccine shows 87% efficacy in clinical trial
The novel, genetically attenuated whole-parasite PfSPZ-LARC2 Vaccine for malaria achieved an 87% efficacy rate in preventing infection during a recent phase 1 trial.
We haven't written up this one. Medical Xpress has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.